CD8A and neoplasm: Consistent with these observations, a recent report confirmed that while A2AR and A2BR blockade by their antagonists shows moderate restoration of MTA-induced inhibition of CD4 and CD8 proliferation in the MTA loss model, direct degradation of MTA by PEGylated MTAP can rescue CD8-dependent anti-tumor response more potently and sensitizes tumor cells to ICB therapy (259).